ArticleAdvanced biomedical research2024
The Impact of Functional Promoter Variants in Interleukin-18 on Susceptibility to Rheumatoid Arthritis in Iranian Population.
Article in Advanced biomedical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of IL6 and IL18 Promoter Polymorphisms on Circulating Cytokine Levels, Gene Expression, and Susceptibility to Rheumatoid Arthritis.International journal of molecular sciences · 2026Article
- Microbiota and mycobiota in chronic inflammatory demyelinating polyneuropathy: clinical and pathophysiological correlations.Frontiers in molecular neuroscience · 2026Article
- Genetic and metabolic inflammation signatures in chronic inflammatory demyelinating polyneuropathy: the role ofFrontiers in molecular neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-18 (IL-18) is recognized for its pro-inflammatory properties and plays a central role in the progression of rheumatoid arthritis (RA). The specific single-nucleotide polymorphisms (SNPs), rs1946518 (-607C>A) and rs187238 (-137G Materials and Methods: In this study, we conducted a case-control analysis with a total of 275 subjects consisting of 135 patients with RA and 140 controls. The high-resolution melting (HRM) method, performed through real-time polymerase chain reaction, was utilized for genotyping these polymorphisms. Results: Regarding the rs1946518 polymorphism, the frequency of AA and CA genotypes and allele A was significantly greater in the control group compared to the RA group (AA vs CC; OR: 0.42; 95%CI [0.198-0.872], CA vs CC; OR: 0.57; 95%CI [0.324-1.001], A vs C; OR: 0.58; 95%CI [0.401-0.836] ( Conclusion: In the rs1946518 polymorphism, the AA and AC genotypes and the A allele demonstrated protective effects in RA. Besides, the CC genotype was associated with some laboratory characteristics in the RA group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.